BioXcel Therapeutics Aligns with FDA Recommendation for Phase 3 Trial for TRANQUILITY Program, Provides Update on Strategic Financing, and Reports Third Quarter 2023 Financial Results
Go back to BioXcel Therapeutics Aligns with FDA Recommendation for Phase 3 Trial for TRANQUILITY Program, Provides Update on Strategic Financing, and Reports Third Quarter 2023 Financial Results| (NASDAQ: BTAI) | Delayed: 1.26 -0.04 (3.08%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.30 | 52 Week High | $ | |||
| Open | $1.28 | 52 Week Low | $ | |||
| Day High | $1.33 | P/E | N/A | |||
| Day Low | $1.25 | EPS | $ | |||
| Volume | 722,543 | |||||
